97 176

Cited 1 times in

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.

DC FieldValueLanguage
dc.contributor.author배숭준-
dc.contributor.author안성귀-
dc.contributor.author윤창익-
dc.contributor.author이학우-
dc.contributor.author정준-
dc.contributor.author차윤진-
dc.date.accessioned2018-07-20T08:37:04Z-
dc.date.available2018-07-20T08:37:04Z-
dc.date.issued2017-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/161328-
dc.description.abstractAIM: The 21-gene recurrence score (RS) predicts a clinical benefit of chemotherapy for individuals with ER-positive/HER2-negative breast cancer. Using in vitro chemoresponse assay, we compared the chemosensitivity according to RS in these patients. METHOD: Among the patients with Oncotype Dx assay, we identified 63 patients who had chemotherapy response assays to doxorubicin based on adenosine triphosphate. The degree of chemosensitivity to doxorubicin was translated into the cell death rate (CDR). The RS was also dichotomized with a cutoff of 26. RESULTS: Of 63 patients, 34 (54%), 17 (27%), and 12 patients (19%) had a low, intermediate, and high RS, respectively. The mean CDR differed significantly according to categorized RS, with 17.3±10.8 in the low RS group vs. 23.6±16.3 in the intermediate RS group vs. 28.8±12.6 in the high RS group (P = 0.024, One-way ANOVA test). The mean CDR was significantly higher in the higher RS (26≥) group compared with the lower RS (<26) group (P = 0.025, the Student's t-test), as well as in the high RS (>30) group compared with the low RS (<18) group (P = 0.012, the Student's t-test). Also, continuous RS and CDR correlated positively (Pearson's R = 0.337; P = 0.007). High RS demonstrated the odds ratio (OR = 26.33; 95% CI = 1.69-410.0) for predicting tumors with chemosensitivity on the multivariate analysis. CONCLUSIONS: The chemosensitivity measured by in vitro chemoresponse assay was different according to the RS. Our findings support that tumors with high RS has the chemosensitivity even though they are luminal/HER2-negative tumors.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherPublic Library of Science-
dc.relation.isPartOfPLOS ONE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Agents/pharmacology-
dc.subject.MESHBiological Assay-
dc.subject.MESHBiomarkers, Tumor/genetics*-
dc.subject.MESHBiomarkers, Tumor/metabolism-
dc.subject.MESHBreast Neoplasms/diagnosis-
dc.subject.MESHBreast Neoplasms/drug therapy*-
dc.subject.MESHBreast Neoplasms/genetics-
dc.subject.MESHBreast Neoplasms/pathology-
dc.subject.MESHCell Death/drug effects-
dc.subject.MESHDoxorubicin/pharmacology*-
dc.subject.MESHDrug Resistance, Neoplasm/genetics*-
dc.subject.MESHEstrogen Receptor alpha/genetics*-
dc.subject.MESHEstrogen Receptor alpha/metabolism-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHKi-67 Antigen/genetics-
dc.subject.MESHKi-67 Antigen/metabolism-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Grading-
dc.subject.MESHNeoplasm Recurrence, Local/diagnosis-
dc.subject.MESHNeoplasm Recurrence, Local/drug therapy*-
dc.subject.MESHNeoplasm Recurrence, Local/genetics-
dc.subject.MESHNeoplasm Recurrence, Local/pathology-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPrognosis-
dc.subject.MESHROC Curve-
dc.subject.MESHReceptor, ErbB-2/deficiency-
dc.subject.MESHReceptor, ErbB-2/genetics*-
dc.subject.MESHTumor Cells, Cultured-
dc.titleChemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Surgery-
dc.contributor.googleauthorSung Gwe Ahn-
dc.contributor.googleauthorSoong June Bae-
dc.contributor.googleauthorChangik Yoon-
dc.contributor.googleauthorYoon Jin Cha-
dc.contributor.googleauthorHak Woo Lee-
dc.contributor.googleauthorSeung Ah Lee-
dc.contributor.googleauthorJoon Jeong-
dc.identifier.doi10.1371/journal.pone.0187679-
dc.contributor.localIdA05345-
dc.contributor.localIdA02231-
dc.contributor.localIdA05369-
dc.contributor.localIdA05015-
dc.contributor.localIdA03727-
dc.contributor.localIdA04001-
dc.relation.journalcodeJ02540-
dc.identifier.eissn1932-6203-
dc.identifier.pmid29117208-
dc.contributor.alternativeNameBae, Soong June-
dc.contributor.alternativeNameAhn, Sung Gwe-
dc.contributor.alternativeNameYoon, Changik-
dc.contributor.alternativeNameLee, Hak Woo-
dc.contributor.alternativeNameJeong, Joon-
dc.contributor.alternativeNameCha, Yoon Jin-
dc.contributor.affiliatedAuthorBae, Soong June-
dc.contributor.affiliatedAuthorAhn, Sung Gwe-
dc.contributor.affiliatedAuthorYoon, Changik-
dc.contributor.affiliatedAuthorLee, Hak Woo-
dc.contributor.affiliatedAuthorJeong, Joon-
dc.contributor.affiliatedAuthorCha, Yoon Jin-
dc.citation.volume12-
dc.citation.number11-
dc.citation.startPagee0187679-
dc.identifier.bibliographicCitationPLOS ONE, Vol.12(11) : e0187679, 2017-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.